227 related articles for article (PubMed ID: 26095669)
1. Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.
Stenger EO; Chiang KY; Haight A; Qayed M; Kean L; Horan J
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1845-52. PubMed ID: 26095669
[TBL] [Abstract][Full Text] [Related]
2. Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
Larsen R; Ryder LP; Svejgaard A; Gniadecki R
Clin Exp Immunol; 2007 Jul; 149(1):23-30. PubMed ID: 17403057
[TBL] [Abstract][Full Text] [Related]
3. Alefacept promotes immunosuppression-free renal allograft survival in nonhuman primates via depletion of recipient memory T cells.
Lee S; Yamada Y; Tonsho M; Boskovic S; Nadazdin O; Schoenfeld D; Cappetta K; Atif M; Smith RN; Cosimi AB; Benichou G; Kawai T
Am J Transplant; 2013 Dec; 13(12):3223-9. PubMed ID: 24165326
[TBL] [Abstract][Full Text] [Related]
4. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
[TBL] [Abstract][Full Text] [Related]
5. Immune reconstitution in patients with Fanconi anemia after allogeneic bone marrow transplantation.
Perlingeiro Beltrame M; Malvezzi M; Bonfim C; Covas DT; Orfao A; Pasquini R
Cytotherapy; 2014 Jul; 16(7):976-89. PubMed ID: 24831839
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis.
Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM
Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586
[TBL] [Abstract][Full Text] [Related]
8. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.
Koenecke C; Shaffer J; Alexander SI; Preffer F; Dombkowski D; Saidman SL; Dey B; McAfee S; Spitzer TR; Sykes M
Exp Hematol; 2003 Oct; 31(10):911-23. PubMed ID: 14550807
[TBL] [Abstract][Full Text] [Related]
9. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
Chamian F; Lin SL; Lee E; Kikuchi T; Gilleaudeau P; Sullivan-Whalen M; Cardinale I; Khatcherian A; Novitskaya I; Wittkowski KM; Krueger JG; Lowes MA
J Transl Med; 2007 Jun; 5():27. PubMed ID: 17555598
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia--a single-center experience.
Wang H; Wang Z; Zheng X; Ding L; Zhu L; Yan H; Guo Z
Cytotherapy; 2013 Sep; 15(9):1118-25. PubMed ID: 23806238
[TBL] [Abstract][Full Text] [Related]
11. Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes.
Li Q; Luo C; Luo C; Wang J; Li B; Ding L; Chen J
Ann Hematol; 2017 Aug; 96(8):1389-1397. PubMed ID: 28623394
[TBL] [Abstract][Full Text] [Related]
12. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
[TBL] [Abstract][Full Text] [Related]
13. CD3
Oved JH; Wang Y; Barrett DM; Levy EM; Huang Y; Monos DS; Grupp SA; Bunin NJ; Olson TS
Biol Blood Marrow Transplant; 2019 Mar; 25(3):549-555. PubMed ID: 30312755
[TBL] [Abstract][Full Text] [Related]
14. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.
Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M
Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939
[TBL] [Abstract][Full Text] [Related]
15. Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions.
Brodszki N; Turkiewicz D; Toporski J; Truedsson L; Dykes J
Orphanet J Rare Dis; 2016 Jan; 11():5. PubMed ID: 26768987
[TBL] [Abstract][Full Text] [Related]
16. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
D'Sa S; Peggs K; Pizzey A; Verfuerth S; Thuraisundaram D; Watts M; White H; Hale G; Waldmann H; Goldstone A; Mackinnon S; Yong K
Br J Haematol; 2003 Oct; 123(2):309-22. PubMed ID: 14531914
[TBL] [Abstract][Full Text] [Related]
17. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases.
Gasior Kabat M; Bueno D; Sisinni L; De Paz R; Mozo Y; Perona R; Arias-Salgado EG; Rosich B; Marcos A; Romero AB; Constanzo A; Jiménez-Yuste V; Pérez-Martínez A
Int J Hematol; 2021 Jul; 114(1):116-123. PubMed ID: 33772729
[TBL] [Abstract][Full Text] [Related]
18. [The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: relationship between infused donor CD4+/CCR7+ T cell subsets and acute graft-versus-host disease].
Choufi B; Thiant S; Trauet J; Cliquennois M; Cherrel M; Boulanger F; Coiteux V; Magro L; Labalette M; Yakoub-Agha I
Pathol Biol (Paris); 2014 Jun; 62(3):123-8. PubMed ID: 24906571
[TBL] [Abstract][Full Text] [Related]
19. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia.
Zecca M; Strocchio L; Pagliara D; Comoli P; Bertaina A; Giorgiani G; Perotti C; Corbella F; Brescia L; Locatelli F
Biol Blood Marrow Transplant; 2014 Apr; 20(4):571-6. PubMed ID: 24462983
[TBL] [Abstract][Full Text] [Related]
20. Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia.
McGuinn C; Geyer MB; Jin Z; Garvin JH; Satwani P; Bradley MB; Bhatia M; George D; Duffy D; Morris E; van de Ven C; Schwartz J; Baxter-Lowe LA; Cairo MS
Pediatr Blood Cancer; 2014 Jul; 61(7):1289-94. PubMed ID: 24623601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
